3SBio Expands Portfolio With Renal Failure Drug Acquisition
HONG KONG – 3SBio Inc. has acquired the patents for a new drug to treat renal failure from the Shanghai Institute of Materia Medica (SIMM) as part of its efforts to expand its offerings linked to diseases of the kidney.
To continue reading subscribe now to BioWorld Asia (formerly International)
Learn More about BioWorld Asia (formerly International)
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.